Sonendo (SONX) Q3 2024 earnings summary

Executive summary

• Revenue for the nine months ended September 30, 2024 was $23.4 million, down 9% year-over-year, with a net loss from continuing operations of $27.2 million, a significant improvement from a $51.2 million loss in the prior year period.

• Q3 2024 revenue was $8.0 million, a 2% decrease year-over-year, with a double-digit console backlog maintained for the third consecutive quarter.

• The company divested its software segment in March 2024, recording a $5.7 million gain from the sale, and now focuses solely on its GentleWave System for root canal therapy.

• Sonendo implemented a 1-for-200 reverse stock split in October 2024 to regain compliance with OTCQX listing requirements after being delisted from the NYSE in late 2023.

• There is substantial doubt about the company's ability to continue as a going concern without additional financing, due to ongoing operating losses and liquidity constraints.

Financial highlights

• Q3 2024 revenue was $8.0 million, nearly flat compared to $8.2 million in Q3 2023; gross margin improved to 41% from 11% year-over-year.

• Operating expenses for Q3 2024 decreased 42% year-over-year to $10.1 million, driven by cost reductions in selling, marketing, G&A, and R&D.

• Net loss for Q3 2024 was $7.5 million, a 56% improvement from $17.0 million in Q3 2023.

• Free cash flow burn decreased to $4.3 million, a 59% year-over-year improvement.

• The company was in compliance with all financial covenants under its term loan as of September 30, 2024.

Outlook and guidance

• Management expects operating expenses to continue decreasing in the remainder of 2024 and into 2025 due to ongoing cost-saving measures and headcount reductions.

• The company anticipates continued net losses for the next several years and will require additional financing to fund operations and growth.

• Management is evaluating financing and strategic alternatives to support future growth.